Kame Alberto Galán-Huerta, Myriam Aseret Zamora-Márquez, Rómulo Omar Flores-Pérez, Paola Bocanegra-Ibarias, Daniel Salas-Treviño, Ana María Guadalupe Rivas-Estilla, Samantha Flores-Treviño, Sonia Amelia Lozano-Sepúlveda, Natalia Martínez-Acuña, Adrián Camacho-Ortiz, Eduardo Pérez Alba, Daniel Arellanos-Soto, Laura Nuzzolo-Shihadeh, Elvira Garza-González
{"title":"白细胞介素1B-31*C促炎等位基因与COVID-19患者严重程度相关性的初步研究","authors":"Kame Alberto Galán-Huerta, Myriam Aseret Zamora-Márquez, Rómulo Omar Flores-Pérez, Paola Bocanegra-Ibarias, Daniel Salas-Treviño, Ana María Guadalupe Rivas-Estilla, Samantha Flores-Treviño, Sonia Amelia Lozano-Sepúlveda, Natalia Martínez-Acuña, Adrián Camacho-Ortiz, Eduardo Pérez Alba, Daniel Arellanos-Soto, Laura Nuzzolo-Shihadeh, Elvira Garza-González","doi":"10.1089/vim.2022.0143","DOIUrl":null,"url":null,"abstract":"<p><p>Individuals with no known comorbidities or risk factors may develop severe coronavirus disease 2019 (COVID-19). The present study assessed the effect of certain host polymorphisms and viral lineage on the severity of COVID-19 among hospitalized patients with no known comorbidities in Mexico. The analysis included 117 unrelated hospitalized patients with COVID-19. Patients were stratified by whether they required intensive care unit (ICU) admission: the ICU group (<i>n</i> = 40) and non-ICU group (<i>n</i> = 77). COVID-19 was diagnosed on the basis of a positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) reverse transcription-polymerase chain reaction (RT-PCR) assay and clinical and radiographic criteria. The presence of the <i>IL1B-31</i> (T/C) polymorphism was determined for all patients using PCR and nucleotide sequencing. Genotyping of the <i>IL-4</i> (-590, T/C) and <i>IL-8</i> (-251, T/A) polymorphisms was performed by the amplification refractory mutation system-PCR method. Genotyping of <i>IL1-RN</i> was performed using PCR. Viral genome sequencing was performed using the ARTIC Network amplicon sequencing protocol using a MinION. Logistic regression analysis identified the carriage of <i>IL-1 B*-31</i> *C as an independent potential risk factor (odds ratio [OR] = 3.1736, 95% confidence interval [CI] = 1.0748-9.3705, <i>p</i> = 0.0366) for ICU admission and the presence of <i>IL-RN</i>*2 as a protective factor (OR = 0.4371, 95% CI = 0.1935-0.9871, <i>p</i> = 0.0465) against ICU admission. Under the codominant model, the CC genotype of <i>IL1B</i>-31 significantly increased the risk of ICU admission (OR: 6.38, 95% CI: 11.57-25.86, <i>p</i> < 0.024). The <i>IL1B</i>-31 *C-<i>IL-4</i>-590 *T haplotype increased the risk of ICU admission (OR = 2.53, 95% CI = 1.02-6.25, <i>p</i> = 0.047). The 42 SARS-CoV-2 genomes sequenced belonged to four clades, 20A-20D. No association was detected between SARS-CoV-2 clades and ICU admission or death. Thus, in patients with no known comorbidities or risk factors, the <i>IL1B</i>-31*C proinflammatory allele was observed to be associated with the risk of ICU admission owing to COVID-19.</p>","PeriodicalId":23665,"journal":{"name":"Viral immunology","volume":"36 4","pages":"241-249"},"PeriodicalIF":1.5000,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":"{\"title\":\"Association of the <i>Interleukin 1B</i>-31*C Proinflammatory Allele with the Severity of COVID-19 Patients: A Preliminary Report.\",\"authors\":\"Kame Alberto Galán-Huerta, Myriam Aseret Zamora-Márquez, Rómulo Omar Flores-Pérez, Paola Bocanegra-Ibarias, Daniel Salas-Treviño, Ana María Guadalupe Rivas-Estilla, Samantha Flores-Treviño, Sonia Amelia Lozano-Sepúlveda, Natalia Martínez-Acuña, Adrián Camacho-Ortiz, Eduardo Pérez Alba, Daniel Arellanos-Soto, Laura Nuzzolo-Shihadeh, Elvira Garza-González\",\"doi\":\"10.1089/vim.2022.0143\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Individuals with no known comorbidities or risk factors may develop severe coronavirus disease 2019 (COVID-19). The present study assessed the effect of certain host polymorphisms and viral lineage on the severity of COVID-19 among hospitalized patients with no known comorbidities in Mexico. The analysis included 117 unrelated hospitalized patients with COVID-19. Patients were stratified by whether they required intensive care unit (ICU) admission: the ICU group (<i>n</i> = 40) and non-ICU group (<i>n</i> = 77). COVID-19 was diagnosed on the basis of a positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) reverse transcription-polymerase chain reaction (RT-PCR) assay and clinical and radiographic criteria. The presence of the <i>IL1B-31</i> (T/C) polymorphism was determined for all patients using PCR and nucleotide sequencing. Genotyping of the <i>IL-4</i> (-590, T/C) and <i>IL-8</i> (-251, T/A) polymorphisms was performed by the amplification refractory mutation system-PCR method. Genotyping of <i>IL1-RN</i> was performed using PCR. Viral genome sequencing was performed using the ARTIC Network amplicon sequencing protocol using a MinION. Logistic regression analysis identified the carriage of <i>IL-1 B*-31</i> *C as an independent potential risk factor (odds ratio [OR] = 3.1736, 95% confidence interval [CI] = 1.0748-9.3705, <i>p</i> = 0.0366) for ICU admission and the presence of <i>IL-RN</i>*2 as a protective factor (OR = 0.4371, 95% CI = 0.1935-0.9871, <i>p</i> = 0.0465) against ICU admission. Under the codominant model, the CC genotype of <i>IL1B</i>-31 significantly increased the risk of ICU admission (OR: 6.38, 95% CI: 11.57-25.86, <i>p</i> < 0.024). The <i>IL1B</i>-31 *C-<i>IL-4</i>-590 *T haplotype increased the risk of ICU admission (OR = 2.53, 95% CI = 1.02-6.25, <i>p</i> = 0.047). The 42 SARS-CoV-2 genomes sequenced belonged to four clades, 20A-20D. No association was detected between SARS-CoV-2 clades and ICU admission or death. Thus, in patients with no known comorbidities or risk factors, the <i>IL1B</i>-31*C proinflammatory allele was observed to be associated with the risk of ICU admission owing to COVID-19.</p>\",\"PeriodicalId\":23665,\"journal\":{\"name\":\"Viral immunology\",\"volume\":\"36 4\",\"pages\":\"241-249\"},\"PeriodicalIF\":1.5000,\"publicationDate\":\"2023-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"3\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Viral immunology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1089/vim.2022.0143\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Viral immunology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1089/vim.2022.0143","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 3
摘要
没有已知合并症或危险因素的个体可能会患上2019年严重冠状病毒病(COVID-19)。本研究评估了墨西哥无已知合并症住院患者中某些宿主多态性和病毒谱系对COVID-19严重程度的影响。该分析包括117名无关的住院COVID-19患者。根据患者是否需要入住重症监护室(ICU)进行分层:ICU组(n = 40)和非ICU组(n = 77)。根据严重急性呼吸综合征冠状病毒2型(SARS-CoV-2)逆转录聚合酶链反应(RT-PCR)检测阳性以及临床和放射学标准诊断为COVID-19。所有患者均采用PCR和核苷酸测序检测il - 1b -31 (T/C)多态性的存在。IL-4 (-590, T/C)和IL-8 (-251, T/A)多态性采用扩增难解突变系统- pcr法进行基因分型。采用PCR对il - 1- rn进行基因分型。病毒基因组测序采用ARTIC网络扩增子测序协议,使用MinION进行。Logistic回归分析发现,IL-1 B*-31 *C携带是ICU入院的独立潜在危险因素(比值比[OR] = 3.1736, 95%可信区间[CI] = 1.0748 ~ 9.3705, p = 0.0366), IL-RN*2存在是ICU入院的保护因素(OR = 0.4371, 95% CI = 0.1935 ~ 0.9871, p = 0.0465)。共显性模型下,CC基因型IL1B-31显著增加ICU入院风险(OR: 6.38, 95% CI: 11.57 ~ 25.86, p il -31 *C-IL-4-590 *T单倍型增加ICU入院风险(OR = 2.53, 95% CI = 1.02 ~ 6.25, p = 0.047)。测序的42个SARS-CoV-2基因组属于4个支系,20A-20D。未发现SARS-CoV-2分支与ICU入院或死亡之间存在关联。因此,在无已知合并症或危险因素的患者中,观察到IL1B-31*C促炎等位基因与新冠肺炎住院风险相关。
Association of the Interleukin 1B-31*C Proinflammatory Allele with the Severity of COVID-19 Patients: A Preliminary Report.
Individuals with no known comorbidities or risk factors may develop severe coronavirus disease 2019 (COVID-19). The present study assessed the effect of certain host polymorphisms and viral lineage on the severity of COVID-19 among hospitalized patients with no known comorbidities in Mexico. The analysis included 117 unrelated hospitalized patients with COVID-19. Patients were stratified by whether they required intensive care unit (ICU) admission: the ICU group (n = 40) and non-ICU group (n = 77). COVID-19 was diagnosed on the basis of a positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) reverse transcription-polymerase chain reaction (RT-PCR) assay and clinical and radiographic criteria. The presence of the IL1B-31 (T/C) polymorphism was determined for all patients using PCR and nucleotide sequencing. Genotyping of the IL-4 (-590, T/C) and IL-8 (-251, T/A) polymorphisms was performed by the amplification refractory mutation system-PCR method. Genotyping of IL1-RN was performed using PCR. Viral genome sequencing was performed using the ARTIC Network amplicon sequencing protocol using a MinION. Logistic regression analysis identified the carriage of IL-1 B*-31 *C as an independent potential risk factor (odds ratio [OR] = 3.1736, 95% confidence interval [CI] = 1.0748-9.3705, p = 0.0366) for ICU admission and the presence of IL-RN*2 as a protective factor (OR = 0.4371, 95% CI = 0.1935-0.9871, p = 0.0465) against ICU admission. Under the codominant model, the CC genotype of IL1B-31 significantly increased the risk of ICU admission (OR: 6.38, 95% CI: 11.57-25.86, p < 0.024). The IL1B-31 *C-IL-4-590 *T haplotype increased the risk of ICU admission (OR = 2.53, 95% CI = 1.02-6.25, p = 0.047). The 42 SARS-CoV-2 genomes sequenced belonged to four clades, 20A-20D. No association was detected between SARS-CoV-2 clades and ICU admission or death. Thus, in patients with no known comorbidities or risk factors, the IL1B-31*C proinflammatory allele was observed to be associated with the risk of ICU admission owing to COVID-19.
期刊介绍:
Viral Immunology delivers cutting-edge peer-reviewed research on rare, emerging, and under-studied viruses, with special focus on analyzing mutual relationships between external viruses and internal immunity. Original research, reviews, and commentaries on relevant viruses are presented in clinical, translational, and basic science articles for researchers in multiple disciplines.
Viral Immunology coverage includes:
Human and animal viral immunology
Research and development of viral vaccines, including field trials
Immunological characterization of viral components
Virus-based immunological diseases, including autoimmune syndromes
Pathogenic mechanisms
Viral diagnostics
Tumor and cancer immunology with virus as the primary factor
Viral immunology methods.